全磁悬浮连续流左心室辅助装置治疗晚期心衰的6个月结局:ELEVATE注册研究
ELEVATE注册研究报道了HeartMate 3全磁悬浮连续流左心室辅助装置获批后的6个月结局。482例患者入组,另有58例匿名生存数据,全队列540例6个月生存率为82±2%。入组初次植入患者中无泵血栓,大出血25%、大感染35%、任何类型卒中5%,功能容量与生活质量显著改善。
要点
- 全队列6个月生存率为82±2%。
- 入组初次植入患者无泵血栓发生。
- 大出血25%、大感染35%、任何卒中5%。
核心结论
- HeartMate 3左心室辅助装置6个月结局显示装置高度可靠、无泵血栓、卒中发生率低,并改善功能容量和生活质量。
研究设计与样本
- ELEVATE为获批后注册研究,482例患者入组提供知情同意,另58例匿名仅收集生存数据。
- 报告初次植入HeartMate 3的463例患者6个月结局及全队列540例生存率。
主要发现
- 全队列6个月生存率为82±2%。
- 入组初次植入患者中泵血栓发生率为0,大出血25%,大感染35%,任何类型卒中5%。
- 功能容量显著改善,6分钟步行距离变化230±191米;生活质量VAS变化31±23。
- 6个月无计划再住院自由率为68±2%。
关键数值与推荐
- 基线平均年龄55.6±11.7岁,男性89%,缺血性病因48%,使用正性肌力药70%。
- 66%为桥接至移植,32%为INTERMACS 1-2级。
临床怎么用
- HeartMate 3可用于晚期心衰患者,6个月内泵血栓风险低、卒中发生率低,功能容量和生活质量改善。
- 需关注大出血和大感染风险,6个月无计划再住院自由率68±2%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The ELEVATE registry was planned to study post-approval outcomes with HeartMate 3™ (HM3), a fully magnetically levitated continuous flow left ventricular assist device (LVAD). METHODS AND RESULTS: A total of 482 patients provided consent to participate in ELEVATE (enrolled cohort). Data collection included baseline demographics, survival, adverse events, quality of life (QOL) [EuroQoL-5 Dimensions visual analogue scale (VAS), and 6-minute walk distance (6MWD)]. An additional 58 patients were implanted with HM3 during the same period but expired or were explanted prior to consent, and only survival data were collected (anonymized cohort). We report the 6-month outcomes of the patients who received HM3 as their primary implant (n = 463) and the survival of the 540 patients in the full cohort (enrolled + anonymized). Baseline characteristics included a mean age of 55.6 ± 11.7 years, 89% male, 48% ischaemic aetiology, and 70% on inotropes. The majority of patients (66%) were bridge-to-transplantation (BTT) and 32% were INTERMACS profile 1-2. Full cohort survival at 6 months was 82 ± 2%. In the enrolled primary implant patients, there was no incidence of pump thrombosis, major bleeding was 25%, major infection 35%, and any stroke type 5%. Functional capacity improved significantly (Δ6MWD 230 ± 191 m) as did QOL (ΔVAS 31 ± 23). Freedom from unplanned rehospitalizations at 6 months was 68 ± 2%. CONCLUSION: The 6-month outcomes of the HM3 LVAD demonstrate a highly reliable, thrombosis free, device with low incidence of stroke and improved functional capacity, and QOL. CLINICALTRIALS. GOV IDENTIFIER: NCT02497950.
引用
- Gustafsson F, Shaw S, Lavee J, et al. Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry. Eur Heart J. 2018. PMID: 30165521. doi:10.1093/eurheartj/ehy513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。